DOCSLIB.ORG

Einstein Healthcare Network Cancer Center Active

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Einstein Healthcare Network Cancer Center Active EINSTEIN HEALTHCARE NETWORK CANCER CENTER ACTIVE CLINICAL TRIALS 1 TABLE OF CONTENTS PAGE Studies by Organ/System 3 Brain 4 - 6 Breast – Neoadjuvant/Adjuvant 6 Breast – Advanced/Metastatic 7-8 Gastrointestinal – Colorectal – Adjuvant 9 Gastrointestinal –Advanced, Metastatic 10 Gastrointestinal –Hepatocellular 11 Gastrointestinal –Pancreatic 12-13 Genitourinary – Prostate 14 Gynecological 15-16 Head and Neck 17 Myeloma 18-20 Lung – NSCLC 21-22 Lung – SCLC/Thymoma, Thymic Carcinoma/Mesothelioma 23-24 Supportive care 25 Multiple cancer diagnoses 26 Trials pending activation 27 ECOG Path. Coordinating Ctr Information “NEW” 10/24/2014 2 BRAIN PROTOCOL CONTACTS Radiation Oncology Investigator – Kenneth Zeitzer, MD 215-456-6280 Coordinator – Jeff Mealey, RN 215-456-6316 No active studies at this time. 3 BREAST PROTOCOL CONTACTS MEDICAL ONCOLOGY Investigator – Mark S. Morginstin, DO 215-456-3880 Coordinator – Joann R. Ackler, RN, OCN, CCRP 215-456-8295 RADIATION ONCOLOGY Investigator – Angelica T. Montesano, MD 215-456-6280 Coordinator – Jeff Mealy, RN 215-456-6316 STUDY# TITLE and ELIGIBILITY CRITERIA THERAPY ADJUVANT NRG BR-003/ A Randomized Phase III Trial of Adjuvant Therapy Arm 1: CIRB-005 Comparing Doxorubicin Plus Cyclophosphamide Followed by Doxorubicin 60 mg/M2 IV Weekly Paclitaxel with or without Carboplatin for Node- Cyclophosphamide 600 mg/m2 IV # Pts: _____ Positive or High-Risk Node Negative Invasive Breast Cancer Q 2 Weeks X 4 cycles Eligibility: Unilateral breast IDC: pT1-3; pN0 – pN3b, Followed by: underwent mastectomy or clear margins on lumpectomy/re- Paclitaxel 80 mg/m2 IV weekly x 12 doses excision; ER, PR, & HER2 negative (please see pgs. 14-15 of protocol for specifics). < 60 days from last surgery to Arm 2: randomization. Adequate organ function/lab values (see pgs. 15 Doxorubicin 60 mg/M2 IV & 16 of protocol); Please refer to section 3.3, pgs. 16 & 17 for Cyclophosphamide 600 mg/m2 IV exclusion criteria details. Initial approval 3/21/2016 Q 2 Weeks X 4 cycles Followed by: CIRB Approval expires 2/17/17 Paclitaxel 80 mg/m2 IV weekly x 12 doses and Carboplatin AUC 5 IV Q 3 weeks 4 STUDY# TITLE and ELIGIBILITY CRITERIA THERAPY ADJUVANT RTOG 1014 Partial Breast Re-Irradiation (PBrI) Partial Breast Re-Irradiation (PBrI) 3D-Conformal External Beam 3D-Conformal External Beam A Phase II study of Repeat 1.5 GY x 15 (BID) to 45 Gy Total 1.5 GY x 15 (BID) to 45 Gy Total Breast Preserving Surgery and Patient Population: 3D-Conformal � Histopathologic confirmation via lumpectomy of local in-breast Partial Breast Re-Irradiation ipsilateral recurrence (PBrI) for Local Recurrence of � Final breast surgery (lumpectomy and/or final re-excision) within Breast Carcinoma 42 days prior to study entry; � Initial lumpectomy followed by whole breast radiation >1 year Closed to accrual 6/18/13 prior to study entry; � Ipsilateral breast mammogram and MRI within 120 days prior to study entry. Contralateral breast mammogram within 12 months of study entry. � Negative histologic margins of resection, no tumor on ink, following breast-preserving surgery of local recurrence. RTOG 1005 Patient Population: ARM 1: Standard fractionation pStage 0, I, II Breast Cancer resected by lumpectomy Whole Breast 50.0 Gy/25 fractions/2.0 Gy daily ypStage 0, I,II Breast Cancer resected by lumpectomy that Optional fractionation of 42.7Gy in 16 fractions permissible A PHASE III TRIAL OF followed neoadjuvant systemic therapy Sequential Boost 12.Gy/6 fractions/2.0 Gy daily or ACCELERATED WBI WITH 14.0Gy/7fractions/2Gy daily HYPOFRACTIONATION PLUS ARM 2: Hypofractionation (15 fractions total) CONCURRENT BOOST Whole Breast 40 Gy/15 fractions/2.67 Gy daily Vs. STANDARD WBI Concurrent boost 48.0 Gy/3.2 Gy daily PLUS SEQUENTIAL BOOST FOR EARLY-STAGE BREAST CANCER 5 BREAST – Advanced/Metastatic E2112 A Randomized Phase III Trial of Endocrine Therapy plus Arm A: CIRB-004 Entinostat/Placebo in Postmenopausal Patients with Exemestane 25 mg PO daily x 28 days Hormone Receptor-Positive Advanced Breast Cancer Entinostat 5 mg PO days 1, 8, 15, & 22 # Pts. = _____ Eligibility:ER or PR (+) hist. confirmed adeno ca; must be HER2 Arm B: Initial NCI-CIRB AEHN approval 2/4/2016 neg.; Stage III/locally advanced or metastatic not suitable for Exemestane 25 mg PO daily x 28 days therapy of curative intent. Meas or non-meas disease evaluated < Placebo 5 mg PO days 1, 8, 15, & 22 Expires May 20, 2016 4 wks. Please see eligibility checklist for complete entry criteria [protocol section 3.1, pages 19-22]. A cycle = 28 days 6 GI PROTOCOL CONTACTS – ANAL, COLORECTAL, ESOPHAGEAL, GASTRIC, HEPATOCELLULAR, PANCREATIC, & GIST Medical Oncology: Investigator – John Leighton, MD 215-456-3880 Coordinator – Joann R. Ackler, RN, OCN, CCRP 215-456-8295 Radiation Oncology: Investigator – Kenneth Zeitzer, MD 215-456-6285 Coordinator – Jeff Mealy, RN 215-456-6316 GASTROINTESTINAL STUDIES – Esophagus & Gastric – No active studies at this time. 7 GASTROINTESTINAL – Adjuvant/Resected Colon C80702 Phase III Trial of 6 vs. 12 Treatments of Adjuvant Folfox + Arm A: 6 cycles FOLFOX* + Celecoxib/placebo Stage III Celecoxib/Placebo for Patients with Resected Stage III Colon (400 mg daily) Q 2 weeks Cancer (H) N-4285 Arm B: 12 cycles FOLFOX* + Eligibility: Hist. proven Adenocarcinoma; margin > 12 cm from Celecoxib/placebo (400 mg daily) Q 2 weeks # Pts. 5 anal verge & completely resected – R0 resection must be in Accrual goal = 10 / 2,500 operative report; > 1 + lymph node or N1C [see AJCC v. 7]; *Oxaliplatin – 85 mg/m2 IV over 2 hrs, followed synchronous colon primaries OK; PS 0-2; adequate hematologic, by Study Nurse: Joann Ackler renal, & hepatic function; NO -- evidence of residual nodal or *Leucovorin 400 mg/m2 IV over 2 hrs, followed metastatic disease; NSAIDS or ASA use > 3 x/wk; prior or by Closed to accrual concurrent malignancy except in situ skin cancer unless NED > 5 *5-FU 400 mg/m2 IV bolus, then 2400 mg/m2 11.20.15 yrs; neuro-toxicity > Gr 2; history UGI ulcers, bleed, or CIV over 46-48 hrs. perforation x 3yrs; uncontrolled HTN, unstable angina, any history Update #7 approved 3/16/2015 of MI or CVA, NYHA class III/IV CHF; allergy to sulfonamides, NOTE: Treatment must begin > 21 and < 56 IRB Approval Expires celecoxib, NSAIDS. days after definitive resection. September 17, 2016 8 GASTROINTESTINAL – Metastatic Colorectal STUDY# TITLE and ELIGIBILITY CRITERIA THERAPY 2012-PT023-V3.4 Phase III Double-Blinded, Placebo Controlled Study of Study drug (MABp1/placebo) WIRB # 20120762 XilonixTM for Improving Survival in Metastatic Colorectal 7.5 mg/kg IV over 1 hour (+/- 15 minutes) Cancer Patients with Cachexia Q 2 weeks # Pts. =1 (under v2.4); 3 (under v3.4) 1 hour observation will follow each infusion Eligibility: Path. Confirmed metastatic or unresectable, refractory colon cancer (refer to protocol pg 30 for required prior therapies); PS = 0-2; Weight loss in past 6 months must be < 20%; most *all subjects will receive BSC (best supportive care) Total = 4 recent anti-cancer therapy must be > 2; adequate organ function – Accrual goal = 8 / 650 + ++ see specific lab parameters pg 29; serum K & Mg levels must be WNL – OK to replenish to normal prior to enrollment; refer to Study nurse: Joann Ackler pg 31 for specific cardiac status criteria; NO active infections, HIV, Hepatitis B or C; NO TB history (latent or active) or + IGRA; AEs from prior trt must be < grade 1. Restricted therapies:at least 2 weeks since last therapy WIRB Initial Approval Date – including; XRT, chemotherapy, immunotherapy, surgery, 5.13.2013, hormonal therapy or targeted biologics; at least 4 weeks since Version 3.4 -9.22.2015 agents that target IL-1/TNF-alpha. Expires 5.17.2016 9 GASTROINTESTINAL STUDIES –HEPATOCELLULAR – No active trials effective 11/19/2014 STUDY # TITLE and ELIGIBILITY CRITERIA THERAPY 10 GASTROINTESTINAL STUDIES-PANCREATIC STUDY # TITLE and ELIGIBILITY CRITERIA THERAPY RTOG 0848 A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Ist Randomization Treatment for Patients with Resected Head of Pancreas Adenocarcinoma Arm 1: gemcitabine x 5 cycles Arm 2: gemcitabine + erlotinib x 5 cycles Primary head of pancreas invasive adenocarcinoma resected (i.e., removal of Evaluate to confirm no progression Study Nurse: all gross tumor) involving a classic pancreaticoduodenectomy (Whipple) or a 2nd Randomization pylorus preserving pancreaticoduodenectomy; IPMN are eligible; T1-3, N0-1, Arm 3: 1 cycle same chemotherapy as first M-0 eligible. randomization treatment arm Arm 4: 1 cycle same chemotherapy as first randomization treatment arm followed by XRT + capecitabine or 5-FU 11 GU PROTOCOL CONTACTS- Bladder, Prostate, Renal RADIATION ONCOLOGY: Investigator – Kenneth L. Zeitzer, MD 215-456-6280 Coordinator – Jeff Mealey, RN 215-456-6316 ECOG/Other: Investigator – William Tester, MD 215-456-3880 Coordinator – Joann Ackler RN, OCN 215-456-8295 12 Prostate STUDY # TITLE and ELIGIBILITY CRITERIA THERAPY RTOG 0534 A PHASE III TRIAL OF SHORT TERM ANDROGEN Arm 1: PBRT alone PBRT 64.8-70.2 Gy DEPRIVATION WITH PELVIC LYMPH NODE OR PROSTATE BED ONLY RADIOTHERAPY (SPPORT) IN PROSTATE Arm 2: PBRT + NC-STAD PBRT 64.8-70.2 Gy + NC-STAD CANCER for 4-6 months, beginning 2 months before RT PATIENTS WITH A RISING PSA AFTER RADICAL PROSTATECTOMY Arm 3: PLNRT + PBRT + NC-STAD PLNRT to 45 Gy and PBRT to 64.8-70.2 Gy, Lymph node negative adenocarcinoma of the prostate treated with NC-STAD for 4-6 months, beginning 2 months before RT radical prostatectomy Post-radical prostatectomy PSA of ≥ 0.1 - < 2.0 ng/mL; pathologic T3N0/Nx disease or pathologic T2N0/Nx disease, with or without a positive prostatectomy surgical margin; Gleason ≤ 9 RTOG 0938 A Randomized Phase II Trial Of Hypofractionated Radiotherapy For Treatment techniques/machine Favorable Risk Prostate Cancer-RTOG CCOP Study 1.
Load more

Recommended publications
  • Advancement in Diagnostic Imaging of Thymic Tumors
    cancers Commentary Advancement in Diagnostic Imaging of Thymic Tumors Francesco Gentili 1,*, Ilaria Monteleone 2, Francesco Giuseppe Mazzei 1, Luca Luzzi 3, Davide Del Roscio 2, Susanna Guerrini 1 , Luca Volterrani 2 and Maria Antonietta Mazzei 2 1 Unit of Diagnostic Imaging, Department of Radiological Sciences, Azienda Ospedaliero-Universitaria Senese, 53100 Siena, Italy; [email protected] (F.G.M.); [email protected] (S.G.) 2 Unit of Diagnostic Imaging, Department of Medical, Surgical and Neuro Sciences and of Radiological Sciences, University of Siena, Azienda Ospedaliero-Universitaria Senese, 53100 Siena, Italy; [email protected] (I.M.); [email protected] (D.D.R.); [email protected] (L.V.); [email protected] (M.A.M.) 3 Thoracic Surgery Unit, Department of Medical, Surgical and Neuro Sciences, University of Siena, Azienda Ospedaliero-Universitaria Senese, 53100 Siena, Italy; [email protected] * Correspondence: [email protected] Simple Summary: Diagnostic imaging is pivotal for the diagnosis and staging of thymic tumors. It is important to distinguish thymoma and other tumor histotypes amenable to surgery from lymphoma. Furthermore, in cases of thymoma, it is necessary to differentiate between early and advanced disease before surgery since patients with locally advanced tumors require neoadjuvant chemotherapy for improving survival. This review aims to provide to radiologists a full spectrum of findings of thymic neoplasms using traditional and innovative imaging modalities. Abstract: Thymic tumors are rare neoplasms even if they are the most common primary neoplasm of the anterior mediastinum. In the era of advanced imaging modalities, such as functional MRI, dual- Citation: Gentili, F.; Monteleone, I.; Mazzei, F.G.; Luzzi, L.; Del Roscio, D.; energy CT, perfusion CT and radiomics, it is possible to improve characterization of thymic epithelial Guerrini, S.; Volterrani, L.; Mazzei, tumors and other mediastinal tumors, assessment of tumor invasion into adjacent structures and M.A.
    [Show full text]
  • Copy Number Aberrations of Genes Regulating Normal Thymus Development in Thymic Epithelial Tumors
    Published OnlineFirst February 26, 2013; DOI: 10.1158/1078-0432.CCR-12-3260 Clinical Cancer Human Cancer Biology Research Copy Number Aberrations of Genes Regulating Normal Thymus Development in Thymic Epithelial Tumors Iacopo Petrini1, Yisong Wang1, Paolo A. Zucali3, Hye Seung Lee1,4, Trung Pham1, Donna Voeller1, Paul S. Meltzer2, and Giuseppe Giaccone1 Abstract Purposes: To determine whether the deregulation of genes relevant for normal thymus development can contribute to the biology of thymic epithelial tumors (TET). Experimental Design: Using array comparative genomic hybridization, we evaluated the copy number aberrations of genes regulating thymus development. The expression of genes most commonly involved in copy number aberrations was evaluated by immunohistochemistry and correlated with patients’ outcome. Correlation between FOXC1 copy number loss and gene expression was determined in a confirmation cohort. Cell lines were used to test the role of FOXC1 in tumors. Results: Among 31 thymus development-related genes, PBX1 copy number gain and FOXC1 copy number loss were presented in 43.0% and 39.5% of the tumors, respectively. Immunohistochemistry on a series of 132 TETs, including those evaluated by comparative genomic hybridization, revealed a correlation between protein expression and copy number status only for FOXC1 but not for PBX1. Patients with FOXC1- negative tumors had a shorter time to progression and a trend for a shorter disease-related survival. The correlation between FOXC1 copy number loss and mRNA expression was confirmed in a separate cohort of 27 TETs. Ectopic FOXC1 expression attenuated anchorage-independent cell growth and cell migration in vitro. Conclusion: Our data support a tumor suppressor role of FOXC1 in TETs.
    [Show full text]
  • Pulmonary in Trisomy 18 (T18) and Has Been Described Also in Several Disorders Other Than T18
    ANNUAL MEETING ABSTRACTS 449A 1867 Infections in a Children’s Hospital Autopsy Population abstract, is useful and may serve as a guideline to define CH, with linear regression +20% J Springer, R Craver. Louisiana State University Health Science Center, New Orleans, of T18 cases and/or linear regression -20% of control cases being the borderline for CH. LA. Background: Despite advances in antimicrobial therapy, infections/inflammatory 1869 Expression of Disialoganglioside GD2 in Neuroblastomas of lesions may frequently cause or contribute to death in children. Patients Treated with Immunotherapy Design: We retrospectively reviewed all autopsies performed at a children’s hospital T Terzic, P Teira, S Cournoyer, M Peuchmaur, H Sartelet. Centre Hospitalier from 1986-2009 and categorized infectious complications as 1)underlying cause Universitaire Sainte-Justine, Montreal, QC, Canada; Hopital Universitaire Robert- of death,2) mechanism of death complicating another underlying cause of death,3) Debre, Paris, France. contributing to death 4) agonal or infections immediately before death 5) incidental. Background: Neuroblastoma, a malignant neoplasm of the sympathetic nervous Infectious complications were then separated into 3-8 year groups to identify trends system, is one of the most aggressive pediatric cancers with a tendency for widespread over the years. dissemination, relapse and a poor long term survival, despite intensive multimodal Results: There were 1369 deaths over 24 years, 608 (44%) underwent autopsy at treatments. Recent use of immunotherapy (a chimeric human-murine monoclonal the hospital, another 122 (8.9%) were coroner’s cases not performed at the hospital. antibody ch14.18 directed against a tumor-associated antigen GD2, a disialoganglioside) There were 691 infectious conditions in 401 children (66%, 1.72 infections/infected to treat minimal residual disease has shown improvement in event-free and overall patient).There were no differences in the percentage of autopsies with infections over survival of high-risk neuroblastomas.
    [Show full text]
  • Redalyc.POSTERS EXPOSTOS
    Revista Portuguesa de Pneumología ISSN: 0873-2159 [email protected] Sociedade Portuguesa de Pneumologia Portugal POSTERS EXPOSTOS Revista Portuguesa de Pneumología, vol. 23, núm. 3, noviembre, 2017 Sociedade Portuguesa de Pneumologia Lisboa, Portugal Disponível em: http://www.redalyc.org/articulo.oa?id=169753668003 Como citar este artigo Número completo Sistema de Informação Científica Mais artigos Rede de Revistas Científicas da América Latina, Caribe , Espanha e Portugal Home da revista no Redalyc Projeto acadêmico sem fins lucrativos desenvolvido no âmbito da iniciativa Acesso Aberto Document downloaded from http://www.elsevier.es, day 06/12/2017. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited. POSTERS EXPOSTOS PE 001 PE 002 A PLEASANT FINDING MALIGNANT CHEST PAIN A Pais, AI Coutinho, M Cardoso, A Pignatelli, C Bárbara A Pais, C Pereira, C Antunes, V Pereira, AI Coutinho, A Feliciano, Centro Hospitalar de Lisboa Norte C Quadros, A Ribeiro, L Carvalho, C Bárbara Centro Hospitalar de Lisboa Norte Key-words: mass, debridement, hamartoma Key-words: pain, S100, sarcoma 37-year-old male patient, salesman. Sporadic smoker. With a past history of allergic rhinitis and chronic gastritis. With no usual 26-year-old male patient, supermarket employee. Smoker of 10 medication. In January 2017, he was diagnosed with a respiratory pack-year. Past history of bronchial asthma in childhood. No rel - infection, having completed ten days of empirical antibiotic ther - evant family history. Without usual ambulatory medication. With apy with amoxicillin / clavulanic acid, with clinical improvement. a history of dry cough and chest pain in the posterior region of In May 2017, he underwent thoracic xray, which revealed homoge - the left hemithorax, for about two years, having had at that time, neous opacity of triangular morphology in the middle lobe of the chest X-ray without pathological findings, and the clinical picture right lung.
    [Show full text]
  • (NCCN Guidelines®) Thymomas and Thymic Carcinomas
    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Thymomas and Thymic Carcinomas Version 2.2019 — March 11, 2019 NCCN.org Continue Version 2.2019, 03/11/19 © 2019 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. NCCN Guidelines Index NCCN Guidelines Version 2.2019 Table of Contents Thymomas and Thymic Carcinomas Discussion *David S. Ettinger, MD/Chair † Ramaswamy Govindan, MD † Sandip P. Patel, MD ‡ † Þ The Sidney Kimmel Comprehensive Siteman Cancer Center at Barnes- UC San Diego Moores Cancer Center Cancer Center at Johns Hopkins Jewish Hospital and Washingtn University School of Medicine Karen Reckamp, MD, MS † ‡ *Douglas E. Wood, MD/Vice Chair ¶ City of Hope National Medical Center Fred Hutchinson Cancer Research Matthew A. Gubens, MD, MS † Center/Seattle Cancer Care Alliance UCSF Helen Diller Family Gregory J. Riely, MD, PhD † Þ Comprehensive Cancer Center Memorial Sloan Kettering Cancer Center Dara L. Aisner, MD, PhD ≠ University of Colorado Cancer Center Mark Hennon, MD ¶ Steven E. Schild, MD § Roswell Park Cancer Institute Mayo Clinic Cancer Center Wallace Akerley, MD † Huntsman Cancer Institute Leora Horn, MD, MSc † Theresa A. Shapiro, MD, PhD Þ at the University of Utah Vanderbilt-Ingram Cancer Center The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Jessica Bauman, MD ‡ † Rudy P. Lackner, MD ¶ Fox Chase Cancer Center Fred & Pamela Buffett Cancer Center James Stevenson, MD † Case Comprehensive Cancer Center/ Ankit Bharat, MD ¶ Michael Lanuti, MD ¶ University Hospitals Seidman Cancer Center Robert H. Lurie Comprehensive Cancer Massachusetts General Hospital Cancer Center and Cleveland Clinic Taussig Cancer Institute Center of Northwestern University Ticiana A.
    [Show full text]
  • Cigna Chest Imaging Guidelines
    Cigna Medical Coverage Policies – Radiology Chest Imaging Guidelines Effective February 1, 2021 ____________________________________________________________________________________ Instructions for use The following coverage policy applies to health benefit plans administered by Cigna. Coverage policies are intended to provide guidance in interpreting certain standard Cigna benefit plans and are used by medical directors and other health care professionals in making medical necessity and other coverage determinations. Please note the terms of a customer’s particular benefit plan document may differ significantly from the standard benefit plans upon which these coverage policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a coverage policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the coverage policy. In the absence of federal or state coverage mandates, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of: 1. The terms of the applicable benefit plan document in effect on the date of service 2. Any applicable laws and regulations 3. Any relevant collateral source materials including coverage policies 4. The specific facts of the particular situation Coverage policies relate exclusively to the administration of health benefit plans. Coverage policies are not recommendations for treatment and should never be used as treatment guidelines. This evidence-based medical coverage policy has been developed by eviCore, Inc. Some information in this coverage policy may not apply to all benefit plans administered by Cigna. These guidelines include procedures eviCore does not review for Cigna.
    [Show full text]
  • Cystic Thymomas and Thymic Cysts a Review
    Thorax (1967), 22, 408. Cystic thymomas and thymic cysts A Review N. H. DYER' From the London Hospital, E.I Six cases of large thymic cyst are described; five were cystic thymomas and one was non- neoplastic. Two of the thymomas were not only grossly degenerate but showed severe chronic inflammatory change, so that the diagnosis might be missed. The classification of cysts into congenital, inflammatory, and neoplastic groups is discussed. Cystic teratomata of the thymus, lymphatic cysts, and bronchogenic cysts are classed separately since thymic location does not affect their natural history. Cystic thymomas are still not well known clinically, and the literature on the subject is reviewed. It is probable that quite a few non-specific cysts of the anterior mediastinum are of thymic origin. Tumours of the thymus are not as rare as was TABLE I formerly supposed (Brit. med. J., 1963) although MEDIASTINAL TUMOURS AND CYSTS (1950-65) their relative incidence varies greatly in different series of primary mediastinal tumours and cysts Type of Tumour No. and ranges from 7-5% to 43% (Le Roux, 1961). Neurogenous .36 Benign .30 Thymic cysts, however, have received scant atten- Malignant .. 3 most have failed Neuroblastoma.. 3 tion in the literature and reports Teratoma.11 to emphasize the different varieties of the lesion. Benign. 8 Malignant .. 3 In particular, the tendency to gross cyst formation Thymoma .24 which has been Thymic carcinoma 2 in thymomas, long recognized by Thymic cyst 1 pathologists, is often not appreciated by clinicians. Bronchogenic cyst.. 5 Pericardial cyst. 4 When the cystic element predominates the thymic Lymphatic cyst/lymphangioma.2 of the tumour be missed Haemangioma.
    [Show full text]
  • Exotics Oncology: Special Focus on Updates on Therapies for Rabbits & Ferrets
    Exotics Oncology: Special Focus on Updates on Therapies for Rabbits & Ferrets La’Toya Latney, DVM Exotic Companion Animal Medicine Service Penn Vet THYMOMAS IN RABBITS Rabbits possess a persistent thymus, which does not involute with age. The thymus is comprised of thymic epithelium, reticuloendothelial tissue, and lymphoid tissue. Primary thymic neoplasms recognized in rabbits include (1) benign neoplasm of thymic epithelial cells, (2) thymic carcinoma, a rare malignant neoplasm of the epithelial cells and (3) thymic lymphoma, which is a malignant neoplasm of the lymphoid tissue of the thymus. Clinically, thymomas are diagnosed as lymphoid-rich, epithelial-rich, or mixed lymphoepithelial. The incidence in pet rabbits is largely unknown, however in one retrospective study, thymomas comprised 7% of all neoplasms in 55 colony rabbits in rabbits 2-4 years of age in 1949. More recently, in a retrospective evaluation of 1,100 female rabbits more than 2 years of age submitted for necropsy over a 17-year period, 4 cases of the 234 rabbits that had neoplasia were thymomas (Andres 2012). Literary resources are mainly comprised of clinical case reports (Guzman, Kunzel, Pilny, Bennett, Kovalik, Wagner, Quesenberry, Florizoone, Vernau). Based on current literature, there is no specific sex predisposition, but the common age range is 3-10 years of age, with the median age of 6 years (Kunzel, Andres). Certain breeds have been consistently prominent in clinical case reports, including Netherland dwarves and Lionhead rabbits (Kunzel, Andres). Clinical signs commonly include severe dyspnea and nasal flaring, third eyelid protrusion, orthopneic body position, and bilateral exophthalmos due to caval compression resulting in the pooling of blood in retrobulbar venous plexus.
    [Show full text]
  • An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances
    pharmaceuticals Review An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances Valentina Tateo 1 , Lisa Manuzzi 1, Claudia Parisi 1 , Andrea De Giglio 1,2,* , Davide Campana 1,2 , Maria Abbondanza Pantaleo 1,2 and Giuseppe Lamberti 1,2 1 Department of Experimental, Diagnostic and Specialty Medicine, Policlinico di Sant’Orsola University Hospital, Via P. Albertoni 15, 40138 Bologna, Italy; [email protected] (V.T.); [email protected] (L.M.); [email protected] (C.P.); [email protected] (D.C.); [email protected] (M.A.P.); [email protected] (G.L.) 2 Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via P. Albertoni 15, 40138 Bologna, Italy * Correspondence: [email protected]; Tel.: +39-0512142639 Abstract: Thymic tumors are a group of rare mediastinal malignancies that include three differ- ent histological subtypes with completely different clinical behavior: the thymic carcinomas, the thymomas, and the rarest thymic neuroendocrine tumors. Nowadays, few therapeutic options are available for relapsed and refractory thymic tumors after a first-line platinum-based chemotherapy. In the last years, the deepening of knowledge on thymus’ biological characterization has opened possibilities for new treatment options. Several clinical trials have been conducted, the majority with disappointing results mainly due to inaccurate patient selection, but recently some encouraging results have been presented. In this review, we summarize the molecular alterations observed in Citation: Tateo, V.; Manuzzi, L.; thymic tumors, underlying the great biological differences among the different histology, and the Parisi, C.; De Giglio, A.; Campana, D.; promising targeted therapies for the future.
    [Show full text]
  • Coincidence of Thymoma and Breast Cancer and in a 56-Year-Old Female Patient
    Case Report Page 1 of 7 Coincidence of thymoma and breast cancer and in a 56-year-old female patient Evangelia Athanasiou1, Electra Michalopoulou-Manoloutsiou1, Mattheos Bobos1, Dimitris I. Hatzibougias1, Paul Zarogoulidis2, Nikolos Katsikogiannis3, Eirini Sarika3, Ilias Karapantzos4, Nikolaos Barbetakis5, Dimitrios Paliouras5, Fotis Chatzinikolaou6, Charalampos Charalampidis7, Ioanna Kougioumtzi3, Alexandros Kolettas8, Andreas Bakas8, Keraso Tzelepi9, Efstratios Kalaitzis9, Kosmas Tsakiridis8 1“Microdiagnostics” Ltd., Thessaloniki, Greece; 2Pulmonary Department-Oncology Unit, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece; 3Surgery Department (NHS), University General Hospital of Alexandroupolis, Alexandroupolis, Greece; 4Ear, Nose and Throat Department, “St. Luke’s”, Private Hospital, Panorama, Thessaloniki, Greece; 5Thoracic Surgery Department, 6Pathology Department, “Theagenio” Cancer Hospital, Thessaloniki, Greece; 7Department of Anatomy, Democritus University of Thrace, Alexandroupolis, Greece; 8Thoracic Surgical Department, 9Surgical Department, “St. Luke’s”, Thessaloniki, Greece Correspondence to: Paul Zarogoulidis, MD, PhD. Pulmonary Department-Oncology Unit, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. Email: [email protected]. Abstract: We present a case of a 56-year-old female, with a familial history of breast, lung and brain cancer, which revealed a breast tumor, located in the upper outer quadrant of the left breast. During
    [Show full text]
  • Multiple Inflammatory Cytokine-Productive Thyl-6 Cell Line Established from a Patient with Thymic Carcinoma
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Community Repository of Fukui Multiple Inflammatory Cytokine-Productive ThyL-6 Cell Line Established from a Patient with Thymic Carcinoma Kunihiro Inai 1, Kazutaka Takagi 2, Nobuo Takimoto 1, Hiromi Okada 1, Yoshiaki Imamura 3, Takanori Ueda 2, Hironobu Naiki 1, and Sakon Noriki 4 1 Division of Molecular Pathology, Department of Pathological Sciences, 2 Division of Hematology and Cardiology, Department of General Medicine, 3 Division of Surgical Pathology and 4 Division of Tumor Pathology, Department of Pathological Sciences, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan Corresponding author: Kazutaka Takagi, M.D. 23-3 Matsuoka-Shimoaizuki, Eiheiji, Fukui 910-1193, Japan Phone: +81-776-61-3111, ext. 2296 Fax: +81-776-61-8109 E-mail: [email protected] Running title: Inflammatory Cytokine Productive ThyL-6 Cell 1 Summary Thymic epithelial cells can produce many kinds of cytokines, and interleukin (IL)-6-producing thymic carcinoma cases have been reported. However, a cytokine-producing human thymic tumor cell line has not previously been established. In this paper, we report a novel, multiple inflammatory cytokine-productive cell line that was established from a patient with thymic carcinoma. This cell line, designated ThyL-6, positively expressed epithelial membrane antigen, cytokeratins, vimentin intermediate filament, and CD5, although hematological markers were not present in the cells. Cytokine antibody array analysis showed that the cells secreted several cytokines including IL-1α, IL-6, IL-8, RANTES, soluble TNFα-receptor 1, VEGF, and CTLA into the culture medium.
    [Show full text]
  • Thymomas and Thymic Carcinomas
    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Thymomas and Thymic Carcinomas Version 2.2018 — February 16, 2018 NCCN.org Continue Version 2.2018, 02/16/18 © National Comprehensive Cancer Network, Inc. 2018, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. NCCN Guidelines Index NCCN Guidelines Version 2.2018 Table of Contents Thymomas and Thymic Carcinomas Discussion *David S. Ettinger, MD/Chair † Ramaswamy Govindan, MD † Gregory A. Otterson, MD † The Sidney Kimmel Comprehensive Siteman Cancer Center at Barnes- The Ohio State University Comprehensive Cancer Center at Johns Hopkins Jewish Hospital and Washington Cancer Center - James Cancer Hospital University School of Medicine and Solove Research Institute *Douglas E. Wood, MD/Vice Chair ¶ Fred Hutchinson Cancer Research Matthew A. Gubens, MD, MS † Karen Reckamp, MD, MS † ‡ Center/Seattle Cancer Care Alliance UCSF Helen Diller Family City of Hope Comprehensive Cancer Center Comprehensive Cancer Center Dara L. Aisner, MD, PhD ≠ Gregory J. Riely, MD, PhD † Þ University of Colorado Cancer Center Mark Hennon, MD ¶ Memorial Sloan Kettering Cancer Center Roswell Park Cancer Institute Wallace Akerley, MD † Steven E. Schild, MD § Huntsman Cancer Institute at the Leora Horn, MD, MSc † Mayo Clinic Cancer Center University of Utah Vanderbilt-Ingram Cancer Center Theresa A. Shapiro, MD, PhD ¥ Jessica Bauman, MD ‡ † Rudy P. Lackner, MD ¶ The Sidney Kimmel Comprehensive Fox Chase Cancer Center Fred & Pamela Buffett Cancer Center Cancer Center at Johns Hopkins Joe Y. Chang, MD, PhD § Michael Lanuti, MD ¶ James Stevenson, MD † The University of Texas Massachusetts General Hospital Cancer Center Case Comprehensive Cancer Center/ MD Anderson Cancer Center University Hospitals Seidman Cancer Center Ticiana A.
    [Show full text]